Form 4: Zynex CFO Daniel Moorhead Sells 10,000 Shares Under 10b5-1 Trading Plan

Zynex Inc.'s Chief Financial Officer, Daniel Moorhead, sold 10,000 shares of common stock at an average price of $7.88 per share on January 2, 2025, under a pre-arranged trading plan.

Summary

• Daniel Moorhead, the Chief Financial Officer of Zynex Inc., sold 10,000 shares of the company's common stock on January 2, 2025.
• The sale was executed at a weighted average price of $7.88 per share.
• This transaction was conducted under a Rule 10b5-1 trading plan that Mr. Moorhead adopted on July 31, 2024.
• Following the transaction, Mr. Moorhead directly owns 26,299 shares of Zynex common stock.

Sentiment

Score: 5

Explanation: The document is a routine disclosure of an insider stock sale under a pre-arranged plan. It is neither positive nor negative in itself.

Risks

• Insider selling, even under a pre-arranged plan, can sometimes be perceived negatively by the market.

Industry Context

This is a routine disclosure of an insider transaction. It is common for executives to use 10b5-1 plans to manage their stock sales and avoid accusations of insider trading.

Comparison to Industry Standards

• Rule 10b5-1 trading plans are a common practice among executives at publicly traded companies, including those in the medical device industry like Zynex.
• Similar filings are regularly made by executives at companies such as Medtronic, Stryker, and Boston Scientific when they execute pre-planned stock sales.

Stakeholder Impact

• The sale may have a minor impact on shareholder sentiment, but it is unlikely to be significant given the pre-planned nature of the transaction.

Key Dates

Keywords

Zynex, insider trading, Form 4, Daniel Moorhead, Rule 10b5-1, stock sale, ZYXI, CFO